VEGF Gene Transfer for Diabetic Neuropathy
Phase 1
Completed
- Conditions
- Diabetic Neuropathy
- Registration Number
- NCT00056290
- Lead Sponsor
- Losordo, Douglas, M.D.
- Brief Summary
This gene therapy study is being conducted to evaluate intramuscular gene transfer using VEGF (Vascular Endothelial Growth Factor) in patients with diabetic neuropathy in the legs. This condition causes a decrease in feeling and sensation due to diabetes. VEGF is DNA, or genetic material that is injected into the muscles of the leg. Once in the leg, it has been shown to cause new blood vessels to grow under a variety of conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Caritas St. Elizabeth's Medical Center Cardiovascular Research/DVM-4-SMC
🇺🇸Boston, Massachusetts, United States
Columbia University Neuropathy Research Center, Neurological Institute
🇺🇸New York, New York, United States
Caritas St. Elizabeth's Medical Center Cardiovascular Research/DVM-4-SMC🇺🇸Boston, Massachusetts, United States